Literature DB >> 20419431

Methods to evaluate transporter activity in cancer.

Takeo Nakanishi1, Douglas D Ross, Keisuke Mitsuoka.   

Abstract

Plasma membrane transporter proteins play an important role in taking up nutrients into and effluxing xenobiotics out of cells to sustain cell survival. In the last decade, a number of studies have shown that these physiologically important transporters affect absorption, distribution, and excretion of major anticancer agents in clinical use. More importantly, many transporters have been reported to be differentially upregulated in cancer cells compared to normal tissues, suggesting that the differential expression of transporters in cancer cells may become good targets for enhancing drug delivery as well as diagnostic markers for cancer therapy. Hence, utilizing the knowledge of transporter functions likely provides us with the possibility of delivering a drug to the target tissues, avoiding distribution to other tissues, and improving oral bioavailability. This chapter focuses on methodology to analyze the activity of transporters that are involved in drug transport.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20419431     DOI: 10.1007/978-1-60761-700-6_5

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  4 in total

1.  A PET Imaging Strategy to Visualize Activated T Cells in Acute Graft-versus-Host Disease Elicited by Allogenic Hematopoietic Cell Transplant.

Authors:  John A Ronald; Byung-Su Kim; Gayatri Gowrishankar; Mohammad Namavari; Israt S Alam; Aloma D'Souza; Hidekazu Nishikii; Hui-Yen Chuang; Ohad Ilovich; Chih-Feng Lin; Robert Reeves; Adam Shuhendler; Aileen Hoehne; Carmel T Chan; Jeanette Baker; Shahriar S Yaghoubi; Henry F VanBrocklin; Randall Hawkins; Benjamin L Franc; Salma Jivan; James B Slater; Emily F Verdin; Kenneth T Gao; Jonathan Benjamin; Robert Negrin; Sanjiv Sam Gambhir
Journal:  Cancer Res       Date:  2017-06-01       Impact factor: 12.701

2.  Translational phase I trial of vorinostat (suberoylanilide hydroxamic acid) combined with cytarabine and etoposide in patients with relapsed, refractory, or high-risk acute myeloid leukemia.

Authors:  Ivana Gojo; Ming Tan; Hong-Bin Fang; Mariola Sadowska; Rena Lapidus; Maria R Baer; France Carrier; Jan H Beumer; Bean N Anyang; Rakesh K Srivastava; Igor Espinoza-Delgado; Douglas D Ross
Journal:  Clin Cancer Res       Date:  2013-02-12       Impact factor: 12.531

3.  Prostaglandin Transporter (PGT/SLCO2A1) Protects the Lung from Bleomycin-Induced Fibrosis.

Authors:  Takeo Nakanishi; Yoshitaka Hasegawa; Reo Mimura; Tomohiko Wakayama; Yuka Uetoko; Hisakazu Komori; Shin-Ichi Akanuma; Ken-Ichi Hosoya; Ikumi Tamai
Journal:  PLoS One       Date:  2015-04-29       Impact factor: 3.240

4.  A novel role for OATP2A1/SLCO2A1 in a murine model of colon cancer.

Authors:  Takeo Nakanishi; Yasuhiro Ohno; Rika Aotani; Shio Maruyama; Hiroaki Shimada; Shunsuke Kamo; Hiroko Oshima; Masanobu Oshima; John D Schuetz; Ikumi Tamai
Journal:  Sci Rep       Date:  2017-11-29       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.